November Issue is Now Live 

Stay Informed on Latest News and Updates From Fall Clinical 

Around the Practice: Getting Into the Roots of Childhood Atopic Dermatitis 

DermView: Best Practices in Managing Atopic Dermatitis in Skin of Color 

Recognize and Refer: New Directions in the Treatment of Basal Cell Carcinoma

Patients with this rare and severe skin disorder may soon have a new therapeutic option.

Perspectives on Generalized Pustular Psoriasis

Transcript (edited for clarity):
Dr. Bunick. Good morning, and thank you so much for being with us today to discuss your sessions at the South Beach symposium in February, in Florida. But before we get going, if you can just give a little brief summary of your background.


CB: I'm Christopher vNIC. I'm a dermatology researcher and clinician at Yale University where I'm an associate professor. And I have an interest in biochemistry and applying molecular thinking to dermatology patient care.


Great. So tell us about the sessions that you will be both leading and presenting at, at the South Beach symposium.


CB:  I'm very excited about this South Beach symposium in Miami in February. It's a wonderful meeting, and I had the privilege of attending it last year as well. What I really like about this meeting is the way it blends the molecular advances in both cosmetics and clinical dermatology. I feel like it's a really unique blend of the cosmetics and the clinical medical dermatology at a high intellectual level, surrounding mechanisms, therapies for conditions. And I really enjoyed that. And I'm really privileged in the upcoming February meeting at South Beach symposium to actually lead 2 different sessions. 

So the first session I'm going to lead is focused around how to apply genomic technology to improve patient care. And we have a great lineup of speakers. We're really going to delve into concepts like what is precision medicine and what does it mean for better patient care? What are new innovations around genomics and patient care, and even precision medicine and patient care? We're also going to talk about how genomics affect cosmetic therapy. So for those who think that genomics is only for medical diseases in dermatology, that's not true. We're going to talk about cutting edge data regarding genomic and cosmetic outcomes. And also we're going to talk about how to educate patients about genomic therapies, precision medicines. 

The second session that I'm going to lead is focused on box warnings. And in dermatology, with the advent of  JAK inhibitors over the past year, box warnings have become a hot topic. And this session is going to focus on understanding what box warnings are. How do we deal with them? How do we communicate them to patients? How do we use them to decide our practice, our prescription pyramid, in terms of the therapies we choose for our patients?  And I think at the end of this session, dermatologists, health care providers in general, are going to have a really good understanding of the entire world around box warnings and what it means for both the provider and the patient. 

Both the session sound wonderful. Are you going to have time to attend any other sessions by your colleagues?

Absolutely. There's the cutaneous oncology symposium, there's hot topics in aesthetics. And there's a session on skincare products and cosmeceuticals. And that evening, there's even going to be salsa dancing. 

And then on Friday,  we're going to kick off the day with a focus session on alopecia areata, which has been in the news a lot this year: we're going to talk about energy-based devices. And there's going to even be live patient injection tutorials, there's going to be a cadaver workshop. So for those people who want to go back to their medical school and get back in to the cadaver workshop, it's this is the meeting for you.

There's also going to be a Valentine's Day party, and then on Saturday, there's a therapeutic hotline where we talk about all the hottest issues in different therapies. And one of the sessions I'm really excited about, and I don't think gets covered enough in different meetings is a dedicated hour to women and dermatologic disease. And we have a really special speaker who's going to talk about vulvar dermatology, and also another talk on skin diseases in pregnancy. 

There'll be an ice cream social too. And I believe there's going to be a contest for residents, so we're going to find out which residency program is up to par.

Additionally, there will be talks about hidraetinitis suppartiva and there's going to be really exciting giveaway, like a Peloton bike. So, If you don't have a Peloton, you should come because you could win one!

All in all, it will be a wonderful mix of fun, but also serious learning. And it's a wonderful opportunity to network with leaders in the specialty cosmeceutical industry and  clinical industry. Thank you.


Articles

Christopher Bunick, MD, discusses what to expect at the South Beach Symposium, February 9-12 in Miami Beach, Florida.

Christopher Bunick, MD, Gets Excited About the South Beach Symposium

The South Beach Symposium (SBS) meeting was founded in 2002 as a medical and aesthetic dermatology conference that continues to grow into 2023 for its 21st year. The upcoming conference takes place in Miami Beach, Florida, from February 9th through the 12th. Over 600 key opinion leaders will be attending informative sessions and looking for opportunities to network.

This year’s two co-chairs for the 21st Annual South Beach Symposium are Michael H. Gold, MD, and David J. Goldberg, MD, JD, also a 

 Editorial Advisory Board member. The theme of the 2023 meeting, “Deeper Than the Surface,” is based on what sets SBS apart from other dermatology meetings, and how SBS delivers equal parts clinical and aesthetic dermatology education.

The annual 4-day conference is full of informative presentations, expert panel discussions, and networking opportunities. The editors of Dermatology Times® will be covering the conference live in person, reporting on numerous engaging sessions, as well as conducting exclusive interviews with key opinion leaders before the start of the conference. Some of the upcoming content from South Beach Symposium includes:

Hedgehog inhibitors for basal cell carcinoma

See the full SBS agenda at: https://www.livderm.org/sbs-2023-agenda/

Leading industry experts will discuss new data, treatments, and approaches in their respective fields. Specialty sessions will also be taking place Friday through Sunday, covering topics such as sexual and gender diverse dermatology, hair loss, anti-aging, and atopic dermatitis. Make sure to keep up to date with the latest in coverage from the conference and subscribe to 

Dermatology Times® to receive daily email updates

The 2023 South Beach Symposium meeting is just around the corner, kicking off February 9th, 2023. 

What to Expect at the 2023 South Beach Symposium Meeting  

Dustin Portela, DO, a board-certified dermatologist and dermatologic surgeon at Treasure Valley Dermatology in Boise, Idaho.

Dustin Portela, DO, a board-certified dermatologist and dermatologic surgeon at Treasure Valley Dermatology in Boise, Idaho, reviews a case of severe sunburn caused by increased sun sensitivity from medications. 

Opinions expressed are that of Portela and do not express the views or opinions of Dermatology Times®.

Videos

In this week’s Pointers with Dr Portela, the 208SkinDoc, reviews how some medications increase sun sensitivity. 


Pointers with Portela: Sunburn From Medications 

Endo Aesthetics has announced the discontinuation of the production and sale of its collagenase clostridium histolyticum-aaes (Qwo) injection for the treatment of moderate to severe cellulite in the buttocks after industry concerns about the extent and variability of bruising after initial treatment and the potential for prolonged skin discoloration.

“Healthy skepticism should be welcomed and encouraged whenever we witness unsubstantiated claims within the aesthetic dermatology industry. To wit, as physician scientists, we have an obligation to only provide patients with scientifically valid information. For successful practices and trustworthy clinicians, rectitude, integrity, and ethics will continue to reign supreme,” said Will Kirby, DO, FAOCD, chief medical officer of LaserAway, and Editorial Advisory Board member of 

Endo Aesthetics has been working to address these concerns for the past year. In June 2022, Endo launched an open-label study, APHRODITE (NCT05419505), to test various interventions to see if they could help mitigate bruising. Some APHRODITE cohort’s results showed a moderate reduction of bruising area and severity, but none achieved a consistent level of reduced bruising after initiation treatment.

According to Endo Aesthetics, the decision to stop the production and sale of Qwo is expected to result in annualized pre-tax cash savings of approximately $50 million to $60 million and a reduction to Endo's global workforce of approximately 90 full-time positions. Regarding ceasing QWO production and sales, the Company expects to incur pre-tax cash restructuring charges of approximately $15 million to $20 million and record a total pre-tax restructuring charge of approximately $235 million to $250 million in the fourth quarter of 2022.

"Though the news is unfortunate, other colleagues have reported adverse events with the product. The clinical trials showing approximately 84% of subjects experiencing injection site bruising were also appreciated in the "real world" experience with the product. Patients want results with minimal adverse effects, mainly if they invest a lot of money in something they expect makes a significant difference. Perhaps in the future, we can see another product coming down the pipeline that can address moderate to severe cellulite in the buttocks of adult women, as it is a concern in many patients," said Renata Block, PA-C at Advanced Dermatology and Aesthetic Medicine and 

Endo’s collagenase clostridium histolyticum-aaes injection remains approved by the US Food and Drug Administration with clinically proven results and an established safety profile, so practitioners may continue to use unexpired collagenase clostridium histolyticum-aaes injections that they have in stock, as well as order additional supply. Alternatively, practitioners can return unused collagenase clostridium histolyticum-aaes injections purchased before this announcement for a refund. Practices will be notified about these options.

Endo to cease production and sale of Qwo (collagenase clostridium histolyticum-aaes). Endo International. Published December 6, 2022. Accessed December 7, 2022. 

https://investor.endo.com/news-releases/news-release-details/endo-cease-production-and-sale-qwor-collagenase-clostridium

Cancellation is due to concerns about the extent of bruising following initial treatment and prolonged skin discoloration. 

Endo Aesthetics Cancels Production and Sale of Collagenase Clostridium Histolyticum-Aaes Injection 

Eliminating dairy products from pediatric patients with atopic dermatitis (AD) may not provide substantial improvement and could put the patient at risk for developing IgE-mediated food allergies.

Investigators at the Division of Clinical Immunology and Allergy in the Department of Medicine at McMaster University in Ontario, Canada conducted a systematic review and meta-analysis of 10 randomized trials involving 599 patients with AD, undergoing blind, placebo-controlled food challenges. The baseline median of the study mean age was 1.5 years old, and the median of the study mean SCOring Atopic Dermatitis index was 20.7. Compared with no dairy elimination, investigators found low-certainty evidence that it may slightly improve eczema severity (50% vs 41% without dietary elimination improved the SCOring Atopic Dermatitis index by a minimally significant difference of 8.7 points (95% CI, 0 - 17). Furthermore, insufficient data addressed the harm of elimination diets that include randomized controlled trials(RCTS), although indirect evidence suggests that elimination diets may increase the risk of developing Ige-mediated food allergies.

AD is a chronic inflammatory skin disease characterized by relapsing or persistent pruritus, skin pain, lichenification, excoriation, xerosis, and dyspigmentation and is commonly associated with skin infections and atopic comorbidities. It is one of the most common childhood diseases, affecting approximately 6% to 20% of children around the world, as well as being common in adults. The disease burden is high with significant impacts on mental health, sleep, function, and quality of life, and considerable financial costs for patients and caregivers.

One of the study’s lead investigators, Derek Chu, MD, observed that the influence of diet on AD is complex and the use of dietary elimination has historically conflicting views. He said the study’s findings reflect the view from many practitioners that the impact of dietary restriction (benefits, harms, and practical implications) needs to be carefully weighed and reviewed in every case. Chu concluded that the study data reveals the important need for new and robust randomized controlled trials to further improve the evidence regarding all benefits and harms of diets for AD.

Oykhman P, Dookie J, Al-Rammahy H, et al. Dietary Elimination for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis. J Allergy Clin Immunol Pract. 2022 ;10(10):2657-2666.e8. doi:10.1016/j.jaip.2022.06.044. Epub 2022 Jul 19. PMID: 35987995.

New Clinical Trial Evidence Does Not Support Dairy Avoidance as a Beneficial Treatment for Pediatric AD. 

Eliminating dairy for atopic dermatitis may not make significant difference 

RAD is really the first international multidisciplinary conferences addressing atopic dermatitis and the broader comorbidities that that impact patients. There is so much happening in atopic dermatitis, so many new therapies, it's absolutely amazing to see. We are in a golden era of atopic dermatitis. So I'm really excited. We'll have our first mini-symposium addressing treatment updates and atopic dermatitis, really practical grounded for the clinician, what are the new therapies? How do we use them when to use them? There will be abn amazing panel discussion that will be used to highlight different ways in which we can treat our complicated patients with these newer therapies.

And then in the afternoon, we're going to be addressing a really exciting aspect of the of this year's conference, the mental health aspects of the disease. But again, practical information and grounded for the clinician: what can we do to help our patients who are really suffering have a tremendous emotional burden from their disease, along with practical take home messages from really experts in the field who will deal with this on a day to day basis.

There's been a tremendous amount of growth and expansion in terms of new technology but also, as it applies to dermatology in general as well as atopic dermatitis [specifically], so we'll have a great discussion about, you know, some of the new innovations when it comes to digital medicine and things we can do to better monitor patients between visits [as well as] things that we can incorporate into our own treatment decision making.

There's going to be a great debate, a great battle that I'm going to have with professor Eric Simpson about how to really decide when to step up therapy, and who are the right patients that are eligible for systemic treatment. It’s going to be a really fun and informative session. And then there's just an incredible amount of abstracts, over 50 novel research abstracts submitted with some incredibly important stuff from a clinical perspective and from some of the new late breaking research as well. So, stay tuned for the late breaking research session towards the end of the day, some really exciting stuff being presented there. That's going to change the field.

Jonathan Silverberg, MD, PHD, MPHS, talks about the exciting highlights of the Revolutionizing Atopic Dermatitis virtual conference on December 11.

Jonathan Silverberg, MD, PhD, MPHS, Gets Excited About the Upcoming RAD Conference

Eccrine porocarcinoma (EPC), often known as porocarcinoma, is a rare, aggressive tumor that originates from the intraepidermal ducts of eccrine glands.

 The tumor may typically present as an asymptomatic single dome-shaped nodule ranging from 0.4cm to 20cm in size. The lesion can be erythematous and may later progress to painful ulceration.

EPC accounts for about 0.005% to 0.01% of all malignant cutaneous tumors and is characterized by highly invasive and metastatic potential, with lymph nodes and lungs being the most common metastatic sites.

 The tumor is mainly witnessed in the skin of the upper and lower extremities, head and neck region, and trunk of older adults aged over 60 years.

 The lower extremities are the most commonly affected site in women, whereas men mostly witness the tumor in the head and neck region.

Since EPC is a rare condition, limited research has been conducted to address the epidemiology of the disease. Data collected from SEER-18 shows that EPC is more common in men than women, with the highest incidence rates reported among non-Hispanic Whites.

 Although the tumor primarily affects older adults,

 few studies have also reported EPC in younger patients.

A study conducted in England reported the overall incidence rate of EPC at 1.9 per 100,000 people in the country, which is at least ten times higher than in other regions.

 Improvements in histological examination may reduce misdiagnoses and increase the number of diagnosed cases in the future.

The exact cause of EPC is still unknown; however, research revealed that the tumor is most likely to originate from acrosyringium, an intraepidermal duct of the eccrine gland. EPC may emerge either de novo or from a pre-existing benign poroma.

 Moreover, sun exposure and immunosuppression may also play a critical role in EPC tumorigenesis. In rare cases, EPC may also be caused by exposure to certain chemical agents, including benzene glue and poisonous gases.

A recently conducted review published in 

 highlighted the involvement of specific oncogenic drivers, signaling pathways, and cell-cycle dysregulation in EPC tumorigenesis. According to the review, alterations in genes, including 

 and MAPK and PI3K-AKT pathway dysregulation may contribute in the development of EPC.

Due to its rarity and resemblance to basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and seborrheic keratosis and the histological presence of atypical cell types, making an accurate diagnosis of EPC is often challenging to dermatologists.

 Since the tumor mostly appears in older people with no clear clinical features, the focus shifts towards immunohistochemical and histopathological examinations for diagnosis.

Ductal differentiation of poromatous basaloid cells and cytologic atypia with advanced margins are the characteristic histological features of EPC.

Moreover, evidence revealed squamous differentiation, necrosis and ductal formation as the most common histological features of ECP on hematoxylin and eosin (HE) staining. However, it is challenging to diagnose EPC on HE staining alone.

Immunohistochemistry, using EMA, CEA, CK-7, and S-100 protein, is another diagnostic tool that further aid in accurate diagnosis by identifying ductal structures.

 Data shows that EMA is more sensitive than CEA in analyzing EPC tumors; however, these tests are insufficient to make a definitive diagnosis as they also highlight the eccrine ducts of SCC.

Furthermore, EPC shows thin irregular vascular patterns on dermatoscopy, and whitish globular structures on the light brown background make an important EPC dermatoscopic feature. Studies show that atypical vascular patterns combined with milky-red globular structures are specific to EPC.

The prognosis of EPC is generally good in the early stages when it can be effectively treated with surgical excision. However, the prognosis of patients with metastatic EPC is grim, with between 5 and 24 months of overall survival rate.

Currently, no treatment guidelines exist for EPC, and it follows the treatment protocols of sweat gland carcinoma. Mohs micrographic surgery (MMS) or complete circumferential peripheral and deep margin assessment (CCPDMA) is the first line of treatment for patients with EPC.

 However, wide local excision (WLE) can also be performed with a resection margin of at least 2cm from the edge.

A meta-analysis conducted in 2020 revealed that 92.5% of EPC patients were treated with surgical excision; among these cases, WLE was performed in 76.7% of cases.

 However, the role of sentinel lymph node biopsy in treating EPC is unclear and can be considered depending on the patient's condition and advanced disease risk factors.

The efficacy of radiotherapy and chemotherapy for EPC treatment remains controversial. However, few studies suggest that radical radiotherapy can be given post-surgery to reduce recurrence and control metastasis of tumors.

European Review for Medical and Pharmacological Sciences

 highlighted the effectiveness of adjuvant radiotherapy in cases with close or positive margins and unfavorable histology.

Immunotherapy using pembrolizumab can also prove to be an effective novel treatment for metastatic EPC; however, limited evidence exists at present, and further research is needed to establish its efficacy.

Miyamoto K, Yanagi T, Maeda T, Ujiie H. Diagnosis and management of porocarcinoma. 

Seretis K, Bounas N, Lampri E, Lykoudis EG. Eccrine porocarcinoma of the face is a great imitator with aggressive behavior. 

 2022;12(2):e2022085. Published 2022 Apr 1. doi:10.5826/dpc.1202a85

Ragi SD, Moseley I, Ouellette S, Rao B. Epidemiology and survival of eccrine porocarcinoma by sex in the United States: A surveillance, epidemiology, and end results database analysis.

Salih AM, Kakamad F, Baba HO, et al. Porocarcinoma; presentation and management, a meta-analysis of 453 cases. 

 2017;20:74–79. doi: 10.1016/j.amsu.2017.06.027.

Goon PKC, Gurung P, Levell NJ, et al. Eccrine Porocarcinoma of the Skin is Rising in Incidence in the East of England. 

. 2018;98(10):991-992. doi:10.2340/00015555-3000

Shen J, Pan X, Lu Y, Pan D, Ma Y, Zhan R. A case of eccrine porocarcinoma characterized by a progressive increase in the level of Ki-67 index: case report and review of literature. 

 2019;19(1):142. Published 2019 Oct 10. doi:10.1186/s12893-019-0595-4

Worley B, Owen JL, Barker CA, et al. Evidence-based clinical practice guidelines for microcystic adnexal carcinoma: Informed by a systematic review. 

. 2019;155(9):1059-1068. doi:10.1001/jamadermatol.2019.1251

Le NS, Janik S, Liu DT, et al. Eccrine porocarcinoma of the head and neck: Meta-analysis of 120 cases. 

. 2020;42(9):2644-2659. doi:10.1002/hed.26178

Fionda B, Di Stefani A, Lancellotta V, et al. The role of postoperative radiotherapy in eccrine porocarcinoma: a multidisciplinary systematic review. 

 2022;26(5):1695-1700. doi:10.26355/eurrev_202203_28238

Eccrine porocarcinoma is a rare, aggressive tumor that originates from the intraepidermal ducts of eccrine glands. 

Eccrine Porocarcinoma: A Rare Cutaneous Tumor

 Newly released research suggests that new treatments for cutaneous melanoma are responsible for a lower mortality rate among adult patients in the US.

Researchers at the University of Toledo College of Medicine and Life Science in Toledo, Ohio used a population-based cross-sectional study of patients with cutaneous melanoma from the Surveillance, Epidemiology, and End Results (SEER) database from 1975 to 2019. They found the melanoma mortality rate (MMR) decreased from 2013 to 2017 for the first time in the past 40 years in the US, based on the new treatment options that became available in 2013.

Data was analyzed from March 15 to August 15, 2022. Mortality rates reported in the SEER database are per 100 ,000 population and age-adjusted to the 2000 US standard population. The source of mortality data for SEER is the US Mortality Files, National Center for Health Statistics, and Centers for Disease Control and Prevention. The annual percent change (APC) with 95% CI and P value has been used to report long-term trends. The timeline for FDA approvals for melanoma treatment was reviewed to determine any temporal association with MMR trends. Recently, the FDA approved nivolumab and relatlimab, a lymphocyte activation gene 3 (LAG-3)–blocking antibody, for patients with advanced melanoma, which researchers say seems to have a better toxicity profile.

Melanoma is the deadliest skin cancer, historically known for its extremely poor prognosis after metastasis. Globally, it causes an estimated 57 000 deaths annually. The traditional approach for treating metastatic melanoma was sequential chemotherapy, which was associated with little overall survival benefit. The US Food and Drug Administration (FDA) has approved new and effective therapies for melanoma in the last decade, including multiple checkpoint inhibitors such as programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitors and multiple tyrosine kinase inhibitors. Pivotal clinical trials have shown these therapies to be widely effective and associated with an improved survival rate. Historically, the prognosis of metastatic melanoma with cytotoxic chemotherapy has been poor. However, with the use of novel therapies, the 5-year overall survival rate has increased from 5% to greater than 50%.

Kahlon N, Doddi S, Yousif R, et al. Melanoma Treatments and Mortality Rate Trends in the US, 1975 to 2019. JAMA Netw Open. 2022;5(12):e2245269. doi:10.1001/jamanetworkopen.2022.45269

New research suggests new pharmacological therapies are associated with a decrease in melanoma-related deaths. 

Available Treatment Options Helps Decrease Melanoma Mortality Rate 

® Editorial Advisory Board member David Goldberg, MD, JD, is medical director of Skin Laser and Surgery Specialists of New York and New Jersey. He is also director of cosmetic dermatology and clinical research at Schweiger Dermatology Group in New York, New York, and clinical professor of dermatology and past director of Mohs Surgery and Laser Research at the Icahn School of Medicine at Mount Sinai in New York, New York.

This coming February, along with Michael Gold, MD, Goldberg will be chairing the 2023 South Beach Symposium conference, taking place February 9-12, 2023 in Miami Beach, Florida, the 21st year for this particular conference. Dr. Goldberg, who has been lecturing at the symposium for “at least 15 years,” as he noted, will be leading several dynamic sessions at this year’s meeting, including a cutaneous oncology symposium and sessions on what is coming in new energy-based devices for dermatology and new therapeutics, as well as one titled, “Complications and Legal Ramifications: A Call for Cases,” discussing the legal aspects of practicing dermatology. (Dr. Goldberg writes a monthly column, “Legal Eagle,” for 

, in which he shares various legal issues that can come up for dermatology practitioners, and how best to deal with them).

Other don’t-miss sessions at this conference will include Cosmetic Procedures and the Eyes; LGBTQ+ Patients and Aesthetics: Advances in Melanoma: Hedgehog Inhibitors for BCC; Novel Delivery Devices; Genetic Testing; What’s new in JAK Inhibitors Across Dermatologic Conditions; and The Great Debate: Psoriasis. Additionally there will be discussions on new biologics, vulva dermatoses, skin diseases and pregnancy, treatments of hyperpigmentation with lasers, and management of moderate-to-severe hidradenitis suppurativa. The conference agenda offers a mix of the latest treatments and news for both clinical and aesthetic dermatologic practices.

Here, Dr. Goldberg gives a sneak peek of what he will be discussing, and why this is a don’t-miss conference for dermatologic health care providers.

David Goldberg, MD, JD, shares some of the highlights that will be presented at this year's South Beach Symposium in Miami Beach, Florida.

David Goldberg, MD, JD, Talks About the Upcoming South Beach Symposium

® Editorial Advisory Board member Patricia Farris, MD, is a board-certified dermatologist with over 35 years of experience in research, aesthetics, and clinical practice. She is co-founder of the Science of Skincare Summit, a meeting dedicated exclusively to teaching aesthetic professionals about topical skincare and its use in clinical practice. She also serves as a consultant for many well-known cosmetic companies, like L'Oreal, advising on new product development and planning.

In February she will present at, the 2023 South Beach Symposium conference in Miami Beach, Florida. This is the conference's 21st year of providing up-to-the-minute education in medical and aesthetic dermatology from world-renowned expert faculty. 

Farris believes that skincare starts from within, and her 2 sessions will focus on that theory; "Skincare Supplements: Fact or Fiction" and "The Role of Nutrition and Diet in Skin Health".

 The South Beach Symposium will bring together leading dermatology experts  from all over the world and will feature expert panel discussions as well as live patient injections and a cadaver workshop at the Loews Miami Beach Hotel from February 9-12, 2023.

Farris gave  Dermatology Times a preview of her sessions and what she is looking forward to learning about the most at this upcoming conference.

Patricia Farris, MD, shares some of the highlights that will be presented at the 2023 South Beach Symposium in Miami Beach, Florida.

Jonathan Silverberg, MD, PhD, MPHS, Gets Excited About the Upcoming RAD Conference

Eccrine Porocarcinoma: A Rare Cutaneous Tumor

Available Treatment Options Helps Decrease Melanoma Mortality Rate

David Goldberg, MD, JD, Talks About the Upcoming South Beach Symposium

Patricia Farris, MD, Gives Her Thoughts On the Upcoming South Beach Symposium

Perspectives on Generalized Pustular Psoriasis